- Home
- LPA vs ESPR Comparison
LPA vs ESPR Comparison
Compare LPA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- ESPR
- Stock Information
- Founded
- LPA 2013
- ESPR 2008
- Country
- LPA United States
- ESPR United States
- Employees
- LPA N/A
- ESPR N/A
- Industry
- LPA
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- LPA
- ESPR Health Care
- Exchange
- LPA Nasdaq
- ESPR Nasdaq
- Market Cap
- LPA 310.7M
- ESPR 305.0M
- IPO Year
- LPA N/A
- ESPR 2013
- Fundamental
- Price
- LPA $8.98
- ESPR $1.50
- Analyst Decision
- LPA
- ESPR Buy
- Analyst Count
- LPA 0
- ESPR 7
- Target Price
- LPA N/A
- ESPR $6.36
- AVG Volume (30 Days)
- LPA 6.3K
- ESPR 3.9M
- Earning Date
- LPA 03-25-2025
- ESPR 03-04-2025
- Dividend Yield
- LPA N/A
- ESPR N/A
- EPS Growth
- LPA N/A
- ESPR N/A
- EPS
- LPA N/A
- ESPR N/A
- Revenue
- LPA $44,311,428.00
- ESPR $332,314,000.00
- Revenue This Year
- LPA N/A
- ESPR $5.51
- Revenue Next Year
- LPA N/A
- ESPR $1.42
- P/E Ratio
- LPA N/A
- ESPR N/A
- Revenue Growth
- LPA 22.46
- ESPR 185.66
- 52 Week Low
- LPA $6.00
- ESPR $1.47
- 52 Week High
- LPA $525.00
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- ESPR 34.95
- Support Level
- LPA N/A
- ESPR $1.47
- Resistance Level
- LPA N/A
- ESPR $1.61
- Average True Range (ATR)
- LPA 0.00
- ESPR 0.13
- MACD
- LPA 0.00
- ESPR -0.01
- Stochastic Oscillator
- LPA 0.00
- ESPR 7.69
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.